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VOL. 102 NO. 6 / DECEMBER 2014W hile clinical implantationand delivery rates continueto rise in couples attempt-
ing to conceive using assisted
reproductive technology (ART), the
process remains relatively inefﬁcient.
It remains common for euploid em-
bryos with optimal morphokinetic
parameters to be transferred into1591
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONsonographically normal endometrial cavities and still fail to
achieve implantation.
While some of these failures may reﬂect the suboptimal
endocrine milieu accompanying controlled ovarian hyper-
stimulation to attain multifollicular development; implanta-
tion rates are also far from perfect in recipients of oocyte
donation or when transferring cryopreserved embryos where
endometrial preparation and timing should be closer to
physiologic.
While appropriate endocrine dynamics may assure
adequate endometrial preparation and timing, the process of
implantation is a paracrine/juxtacrine-mediated phenome-
non that is controlled locally. Among the factors important
in implantation is hCG (1). Intrauterine infusion of hCG and
exposure of cultured human endometrial epithelial cells has
been shown to upregulate proteins known to be involved
with implantation (2, 3). This has led some investigators to
suggest that endometrial augmentation with infusion of
hCG might lead to enhanced implantation rates.
Mansour et al. found that intraendometrial infusion of
500 IU of hCG during cleavage-stage ET signiﬁcantly
enhanced implantation rates (29.5% in controls vs. 41.6% af-
ter hCG infusion) (4). While these results were most provoca-
tive, several questions remain. The hCG infusion into the
endometrial cavity was dyssynchronous with the physiolog-
ical timing of embryonic hCG secretion, which typically be-
gins at the morula stage (5). At that time, the embryo would
be localized to the fallopian tube in natural conception, mak-
ing it an unusual time to provide a paracrine signal.
Blastocyst ET (day 5 or 6 of embryo development) is
becoming more prevalent, in particular to enhance selection
for elective single ET (eSET). Furthermore, with the broad
clinical application of vitriﬁcation, the practice of frozen ET
(FET) has become increasingly common.
To date there are no published studies on the impact of
endometrial hCG infusion in the perinidatory interval to
determine whether the beneﬁt identiﬁed at the cleavage stage
extends to transfers done at the blastocyst stage. Prior studies
also have not evaluated the impact of hCG infusion in FET
cycles, which may be different from its impact in fresh ETs.
This randomized controlled trial seeks to determine whether
hCG infusion in the minutes before blastocyst transfer mean-
ingfully impacts implantation and delivery rates in fresh and
FET cycles.MATERIALS AND METHODS
Patient Population
All patients undergoing fresh or frozen ET within the ART
program where the female partner was less than 43 years of
age were offered participation. Patients were recruited by
the clinical research team and recovery room staff. Patients
could not be simultaneously participating in another prospec-
tive clinical trial at the center, but there were no other inclu-
sion/exclusion criteria. Speciﬁcally, there were no restrictions
based on any aspect of clinical care before or after the infu-
sion and transfer. All embryos are cultured until day 6 regard-
less of patient age or the size or quality of the embryo cohort.
All fresh transfers within the program occur at the blastocyst1592stage on day 6 of embryonic development. In FET cycles, once
an adequate endometrial thickness and pattern have been
obtained, typically at least 7 mm and trilaminar, IM P in oil
is started and FET is performed on the sixth day of P admin-
istration. Patients, in consultation with their physicians, elect
between transfer of one or two blastocysts. Per practice
routine, real-time quantitative polymerase chain reaction–
based comprehensive chromosome screening (CCS) was
offered to all patients (6, 7). Patients of advanced
reproductive age or with a history of failed implantation
were encouraged to incorporate CCS before ET. Patient
enrollment extended from August 2012 to December 2013.
All participants were followed clinically until their ﬁnal
disposition: pregnancy test for those who failed to conceive,
8 gestational weeks if pregnant with normal growth, or
through the time of any pregnancy loss. Patients with
ongoing gestations were discharged to their obstetricians
for ongoing care, and ﬁnal outcomes were then assessed
after delivery. All data collection was performed at
Reproductive Medicine Associates of New Jersey.Experimental Design
A random number function was used to create variable blocks
of four to eight with patients assigned to the two groups in a
1:1 allocation. Allocation concealment was achieved using
sequentially numbered, opaque, sealed envelopes. Two sets
of randomization schemes were used: one for fresh ET and
one for FET. The study group received endometrial infusion
of ET media (synthetic serum substitute and Medicult Blas-
tAssist from Origio) laden with 500 IU of puriﬁed-urinary
placental hCG (Novarel, Ferring Pharmaceuticals), and the
sham control group received endometrial infusion of ET
media only.
An embryologist opened the randomization envelope on
the afternoon before the day of planned ET to allow time
for preparation and equilibration for the next day's use. The
embryologist prepared the infusion mixture by dissolving
20,000 IU of urinary hCG powder with 0.8 mL of ET media.
The mixture was then stored in a preequilibrated tri-gas incu-
bator. While there are no deﬁnitive studies demonstrating
that there is equivalent potency of hCG at 37C (temperature
of culture incubator), times in vivo do not produce meaning-
ful degradation of the molecule, nor are there any data to
suggest that such a diminution would have occurred.
The usual steps were taken to prepare for ET. The patient
was positioned, and a speculum was placed to visualize the
cervix. The embryologist loaded 20 mL of the ET media with
or without hCG into a Wallace catheter and handed it to the
physician, who then advanced it into the cavity under direct
ultrasound visualization to the approximate depth of the
actual ET that would follow. The media were infused into
the endometrial cavity, and the catheter was discarded. The
embryologist then used a new Wallace catheter to load the
embryo(s) in 20 mL of ET media and handed it to the physician
who then performed the transfer per standard protocol. The
speculum was removed immediately afterwards. The time be-
tween the infusion and ET was less than 3 minutes. Both the
physician performing the transfer and the patient wereVOL. 102 NO. 6 / DECEMBER 2014
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tirety of the study.Statistical Analysis
The primary study outcome was the sustained implantation
rate per embryo. A sustained implantation was deﬁned as a
transferred embryo that reached a viable gestational age
(R24 weeks). Secondary outcomes included the sustained im-
plantation rate per embryo per age group, ongoing pregnancy
rate per transfer, and clinical loss rate per transfer, as deﬁned
by sonographic evidence of a pregnancy that did not result in
a sustained implantation. All rates were compared by a c2
distribution and by calculating 95% conﬁdence intervals
(95% CI) of the relative risk (RR) and risk difference. An alpha
error of less 0.05 was considered signiﬁcant.
A sample-size calculator tool (Open Epi; www.openepi.
com) determined that 778 embryos would be required to
detect an absolute improvement of 10% in sustained implan-
tation rate from the baseline of 50% with a power of 80% and
an alpha error of 0.05.
The protocol was approved by the Institutional Review
Board and registered with clinicaltrials.gov (NCT01643993)
before patient enrollment.FIGURE 1RESULTS
A total of 325 patients elected to participate in the study and
were randomized. Twenty-ﬁve patients declined to partici-
pate after randomization for various reasons; therefore 300
patients received the planned intervention (Supplemental
Fig. 1). A total of 473 embryos were transferred for a mean
transfer order of 1.6 embryos. Comprehensive chromosome
screening was used by 42.3% of study participants.
The mean age of the population was 35.1 years (range,
23.9–42.8 years). Of these, 51% (153/300) were less than
35 years old, 20% (60/300) were 35–37 years old, 21.7%
(65/300) were 38–40 years old, and 7.3% (22/300) were 41–
42 years old.
A total of 148 patients were randomized to receive endo-
metrial infusion of the hCG-laden ET media (hCG group), and
152 patients were randomized to receive the sham infusion of
ET media only (control group). Between the two groups, there
were no differences in age, mean number of embryos trans-
ferred, or the percent using CCS (Table 1).TABLE 1
The study population was similar in the two groups.
Variable Total hCG Sham
Patients (n) 300 148 152
Age (y), (mean  SEM) 35.1  0.2 35.0  0.3 35.1  0.3




% Fresh ET 43.2 44.7 44.0
% SET 42.6 42.1 42.3
Hong. hCG endometrial infusion at transfer. Fertil Steril 2014.
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The primary endpoint of the study was sustained implanta-
tion rate per embryo transferred. There were no differences
in sustained implantation between patients in the group
receiving hCG infusion (112/233; 48.1%) and those in the
control group (106/240; 44.2%; P¼ .39, RR ¼ 1.13; 95% CI,
0.93–1.38; Fig. 1).
Although the study was not powered for subgroup anal-
ysis within age groups, sustained implantation rates within
each age group in the study and control groups were equiva-
lent for age%35, P¼ .73, RR ¼ 1.04, 95% CI, 0.83–1.31; age
35–37, P¼ .72, RR ¼ 1.11, 95% CI, 0.63–1.98; age 38–40,
P¼ .61, RR ¼ 1.12, 95% CI, 0.73–1.72; and age 41–42,
P¼ .66, RR ¼ 1.65, 95% CI, 0.50–5.42 (Supplemental Fig. 2).
A secondary endpoint was the overall ongoing preg-
nancy rate per transfer. Here again, intraendometrial infu-
sion of hCG had no impact on clinical outcomes. The
ongoing pregnancy rate per transfer was 58.8% (87/148) in
the hCG group and 52.0% (79/152) in the control group
(P¼ .24, RR ¼ 1.09, 95% CI, 0.90–1.32), which were equiva-
lent (Fig. 2).
Clinical loss rates were also similar in both groups,
demonstrating that infusion of hCG or ETmedia did not inﬂu-
ence clinical losses. The loss rate per transfer was 11.5% (17/
148) in the hCG group and 7.2% (11/152) in the control group
(P¼ .21, RR ¼ 1.59, 95% CI, 0.77–3.27).Fresh IVF versus Cryopreserved ETs
The data were then stratiﬁed into those undergoing fresh ET
and those involving the transfer of cryopreserved embryos
with exogenous E2 and P support of the endometrium.
A total of 227 embryos were transferred to 132 patients
in fresh IVF cycles. There were no signiﬁcant differences in
the sustained implantation rates in the hCG infusion and
control groups. Speciﬁcally, 52.7% (59/112) of embryos in
the hCG group and 48.7% (56/115) of the embryosSustained implantation rate per embryo was similar in the hCG group
when compared with the sham control group.
Hong. hCG endometrial infusion at transfer. Fertil Steril 2014.
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FIGURE 2
Ongoing pregnancy rate per transfer was similar in the hCG group
when compared with the sham control group.
Hong. hCG endometrial infusion at transfer. Fertil Steril 2014.
FIGURE 3
Sustained implantation rates per embryo were similar in groups of
similar transfer order.
Hong. hCG endometrial infusion at transfer. Fertil Steril 2014.
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a viable gestational age (P¼ .55, RR ¼ 1.09, 95% CI,
0.84–1.40). Ongoing pregnancy rates were also similar in
the hCG group (68.8%, 44/64) and in the control group
(58.9%, 40/68; P¼ .24, RR ¼ 1.17, 95% CI, 0.90–1.51) in
fresh ET cycles.
Evaluation of FET cycles also demonstrated a lack of
beneﬁt to intraendometrial hCG infusion. Of the 246 embryos
transferred into 168 patients in FET cycles, sustained implan-
tation rates were 43.8% (53/121) in the hCG group and 40.0%
(50/125) in the control group (P¼ .55, RR ¼ 1.10, 95% CI,
0.82–1.47). Ongoing pregnancy rates were also similar in
the hCG group (51.2%, 43/84) and in the control group
(46.4%, 39/84; P¼ .54, RR ¼ 1.10, 95% CI, 0.81–1.50).Transfer Order
The number of embryos to be included in each transfer was at
the discretion of the patient and the clinical team and there-
fore was not controlled for within the study. Thus, it was
possible for the groups to have a different prevalence of
SET and double ET. While not impacting the calculation of
sustained implantation rate per embryo transferred, differ-
ences might impact the overall pregnancy rate per transfer
since transfer of two equivalently selected embryos consis-
tently produces a higher pregnancy and delivery rate.
Among the patients randomized to hCG infusion, 16/48
(33%) had SET, whereas 21/47 (45%) of those randomized
to the control group had a SET.
Of the 127 embryos used in SETs, sustained implantation
rates were 50.8% (32/63) in the hCG group and 42.2% (27/64)
in the sham control group (P¼ .34, RR ¼ 1.20, 95% CI, 0.83–
1.75). The remaining 173 patients had two embryos replaced
at ET. Sustained implantation rates were 47.1% (80/170) in
the hCG group and 44.9% (79/176) in the sham control group
(P¼ .69, RR ¼ 1.05, 95% CI, 0.83–1.32; Fig. 3).1594Euploid ETs
A total of 127 patients underwent transfer of 166 chromoso-
mally screened embryos. There were no differences in
outcome between the two groups; implantation rates were
50.6% (43/85) in the hCG group and 48.1% (39/81) in the
sham control group (P¼ .38, RR ¼ 1.05, 95% CI, 0.77–1.43).Study Completion
After 300 ETs had been completed after randomization,
comprising 473 transferred embryos, a planned interim safety
analysis was performed to assure that there was no adverse
effect from the hCG infusion. At that point in the study,
58% power to detect the goal of an absolute difference of
10% in implantation rates had been attained. A futility anal-
ysis was performed, demonstrating that in order for hCG infu-
sion to achieve a 10% beneﬁt in implantation rates over the
sham infusion, the implantation rates in the hCG group would
need to achieve a greater than 20% increase (which is a 40%
relative increase) in implantation rates for the remainder of
the study. Since it is exceedingly unlikely for any one param-
eter or conﬂuence of variables to cause such a dramatic
change, the decision was made that continuation of the study
was futile and enrollment was closed.DISCUSSION
With improvements in the efﬁcacy and safety of ART, there
has been a continued effort to identify interventions that
optimize IVF outcomes with the goal of performing effective
eSET across age groups. The application of extended culture
has been shown to enhance selection and improve implanta-
tion rates, in particular when eSET is performed (8, 9).
Trophectoderm biopsy with CCS has further enhanced eSET
by allowing selective transfer of only euploid blastocysts
(10). Despite these interventions, some euploid embryos still
fail to implant. Potential causes limiting implantation mayVOL. 102 NO. 6 / DECEMBER 2014
Fertility and Sterility®be related to endometrial factors, in particular the complex
embryo/endometrial interactions that occur at the time of
implantation.
Ultimately, this randomized control study demonstrates
that infusion of 500 IU of hCG at the time of blastocyst trans-
fer does not signiﬁcantly improve sustained implantation or
delivery rates. Based on experimental in vitro data, the blas-
tocysts undergoing ET in this trial would already be expected
to be secreting hCG. It is possible that the additional hCG
supplementation at this stage was insufﬁcient to cause an
improvement. It is conceivable that an enhanced signal to
the endometriummay not be sufﬁcient to enhance the perfor-
mance of embryos with limited reproductive potential. Addi-
tional studies are needed to identify why embryos that
otherwise appear optimal fail to implant.
While investigators continue to seek ways to improve em-
bryo selection and optimize the endometrial milieu, addi-
tional signals from the embryo or endometrium may be
identiﬁed. However, increasing the quantity of a missing or
diminished cofactor does not necessarily result in improved
outcomes. Additionally, interventions demonstrated to be
beneﬁcial at the cleavage stage should be cautiously assessed
before implementation at the blastocyst stage. It is possible
that endometrial infusion of hCG may be beneﬁcial before
cleavage-stage ET; however, it is unlikely that this approach
could be used to perform effective eSET across age groups
and improve the safety of IVF. The current trial cannot assess
whether infusion of hCG at an earlier stage, such as on day 3,
would enhance implantation of embryos transferred at the
blastocyst stage. However, this would require an additional
intervention and was felt to not be a practical model in this
study design.
There are other differences, besides the stage of ET, in the
current trial and in the one reported by Mansour et al. that
may also contribute to the difference in conclusions. For
one, the patient populations were different: Mansour et al.
(4) included young women with male factor infertility under-
going their ﬁrst IVF cycles, whereas the current study
included older patients undergoing ETs without regard to
the number of prior failed IVF cycles. However, any potential
beneﬁt of hCG infusion would be expected to be even more
pronounced in a population at higher risk for implantation
failure.
There were also slight differences in the ET technique.
Mansour's group performed cervical compression for several
minutes after the initial hCG infusion was performed; howev-
er, there was no visible evidence of ﬂuid reﬂuxing from the
ectocervical os in the current trial and cervical compression
is not routinely performed in this program. Since the mock
transfer was performed under ultrasound guidance, it is high-
ly unlikely that the hCG infusion did not reach the desired
location.
While this study was terminated after 300 ETs and it was
determined that hCG would not improve the outcome of
blastocyst ETs, the possibility exists that a focused study of
hCG infusion could meaningfully improve the outcome of
eSET. While sustained implantation rates were not signiﬁ-
cantly different in the subset of patients undergoing eSET,
this study was not powered to address this speciﬁc subgroupVOL. 102 NO. 6 / DECEMBER 2014independently. As patients undergoing eSET comprised a
larger proportion of the patients randomized to the control
group in fresh ETs, this also caused ongoing pregnancy rates
to appear higher in the fresh ET group, an effect that does not
persist upon controlling for transfer order. Nonetheless, it
may be worthwhile to explore the impact of hCG infusion
in eSET in future studies.
Like any clinical trial, the current ﬁndings apply to the
population studied and may not be applicable in different
clinical settings or patient subgroups. Additionally, the small
differences in outcomes between the study and control groups
found in this trial might be signiﬁcant if the differences
persisted with a much larger sample size; all data are limited
to the power provided by the number of test subjects included.
Nevertheless, this data set provides strong evidence that
routine inclusion of hCG infusion before blastocyst-stage
ET, whether fresh or frozen, is not beneﬁcial. This trial also
does not address the potential impact of the infusion itself,
as it was designed to isolate the impact of hCG, which neces-
sitates performance of a sham infusion in the control group.
Further study would be required to determine whether infu-
sion alone alters outcomes positively or negatively.
While there is clear evidence that hCG plays an important
role in the perinidatory interval in both animals and humans,
these data do not support its augmentation at the time of
embryo transfer.
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SUPPLEMENTAL FIGURE 1
Study ﬂow. Of the 325 patients who were randomized, 300
underwent the treatment protocol, and 100% of the patients who
underwent the study protocol were included in the data analysis.
There was no loss to follow-up.
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SUPPLEMENTAL FIGURE 2
Sustained implantation rates per embryo per age group. There were
no statistically signiﬁcant differences between the study groups when
stratiﬁed by age group.
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